Matthew Metzger

Company: Oxford BioTherapeutics

Job title: Program, Alliance and Business Development Manager

Bio:

Matthew joined Oxford Biotherapeutics in 2022 and has since been dedicated primarily to external innovation, coordinating and delivering target validation data for partnership programs and business development, developing content and strategies for future partnerships. Currently, he serves as the Alliance and Program Manager of the preclinical programs for both the Roche and Zymeworks collaborations. Additionally, he oversees the internal ADC and bispecific development pipeline. He completed grad school at UC Berkeley and brings years of experience in early-stage biotech startups.

Seminars:

Opportunity to be First-in-Class: Considerations for Collaborations with New Targets 11:10 am

What are the economics of having a new target for others to develop an ADC around? Discussing opportunities to be first-in-class pursuing underexploited targets  Debating the decision to leverage the best linker-payload platform or off-patent technologies, considering the influence on the side effect profileRead more

day: Conference Day Two

ADC Deal-Making: Will Success Lead to More Success? 2:10 pm

Discussing opportunity for and examples of creative deal structures across ADCs  For payloads: Do you need the full ADC payload for a deal? For linkers: What drives deals with different types of linkers?  For target discovery: What are the differences in deal structure versus linkers and payloads? Sharing guidance to progress from a research collaboration…Read more

day: Conference Day Two